Zymenex Sells Clinical Candidate Metazym for EUR 85.6 Million

Zymenex A/S has achieved successful early clinical development of a therapeutic candidate Metazym against the rare, lethal, and genetically caused disease metachromatic leukodystrophy, MLD, which most often affects children at a very young age. This has now resulted in a sale of the therapeutic project to the global specialty biopharmaceutical company Shire plc.

Shire delivers EUR 85.6 Million to Zymenex in an upfront payment for global rights to the Metazym clinical candidate, which has been through clinical phase 1 and is currently in phase 2 in Denmark with European patients. Zymenex also receives EUR 1 Million for transitional services. Zymenex, headquartered in Hillerød, Denmark, is a privately owned company with BankInvest Biomedical Venture and Sunstone Capital as the largest shareholders.

Zymenex CEO Jens Fogh says, "This deal gives Zymenex a validation of the development of treatment options for other life-threatening diseases. Zymenex already has other similar projects in their pipeline."

Thomas Tscherning, Chairman of the Board in Zymenex and partner with BankInvest´s Biomedical Venture group, is proud to see Danish research and development efforts recognized by global pharmaceutical companies. For BankInvest and Sunstone Capital this breakthrough is visible proof, that a focused strategy, strong management, and financial staying power are key success criteria in the biotech venture arena. "Zymenex has from the very beginning focused on orphan drugs for LSD. Market focus and high quality research in all aspects of the development process are the basis for the company's success", says Sten Verland from Sunstone Capital and emphasizes, that Zymenex has a strong pipeline with the potential to develop further successes.

For further information please contact:

Jens Fogh,

President, CEO

Tel: + 45 48 25 00 54.

Email zxmail@zymenex.com

Or visit: www.zymenex.com